Header Logo

Connection

DANIEL DESALVO to Insulin Infusion Systems

Back to Details
This is a "connection" page, showing publications DANIEL DESALVO has written about Insulin Infusion Systems.
DANIEL DESALVO
Connection Strength
5.252
Insulin Infusion Systems
  1. Safety and Glycemic Outcomes Among Youth With New-Onset Type 1 Diabetes Using a Tubeless Automated Insulin Delivery System. J Diabetes Res. 2026; 2026(1):e2896084.
    View in: PubMed
    Score: 0.926
  2. Glycemic Outcomes Persist for up to 2 Years in Very Young Children with the Omnipod? 5 Automated Insulin Delivery System. Diabetes Technol Ther. 2024 06; 26(6):383-393.
    View in: PubMed
    Score: 0.814
  3. Social Determinant of Health Impact on Diabetes Device Use and Clinical Outcomes in Youth with Type 1 Diabetes. Pediatr Diabetes. 2023; 2023:4751595.
    View in: PubMed
    Score: 0.796
  4. Diabetes Device Use and Glycemic Control among Youth with Type 1 Diabetes: A Single-Center, Cross-Sectional Study. J Diabetes Res. 2018; 2018:5162162.
    View in: PubMed
    Score: 0.553
  5. International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024 Diabetes Technologies: Glucose Monitoring. Horm Res Paediatr. 2024; 97(6):615-635.
    View in: PubMed
    Score: 0.217
  6. Psychosocial outcomes with the Omnipod? 5 Automated Insulin Delivery System in caregivers of very young children with type 1 diabetes. Diabetes Obes Metab. 2024 12; 26(12):5569-5579.
    View in: PubMed
    Score: 0.212
  7. Real-World Evidence of Omnipod? 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes. Diabetes Technol Ther. 2024 08; 26(8):514-525.
    View in: PubMed
    Score: 0.203
  8. Psychosocial Outcomes with the Omnipod? 5 Automated Insulin Delivery System in Children and Adolescents with Type 1 Diabetes and Their Caregivers. Pediatr Diabetes. 2023; 2023:8867625.
    View in: PubMed
    Score: 0.194
  9. Hybrid Closed-Loop Systems and Glycemic Outcomes in Children and Adults With Type 1 Diabetes: Real-World Evidence From a U.S.-Based Multicenter Collaborative. Diabetes Care. 2022 08 01; 45(8):e118-e119.
    View in: PubMed
    Score: 0.183
  10. Sources and Valence of Information Impacting Parents' Decisions to Use Diabetes Technologies in Young Children <8 Years Old with Type 1 Diabetes. Diabetes Technol Ther. 2020 09; 22(9):697-700.
    View in: PubMed
    Score: 0.155
  11. Insulin Pump Use in Young Children with Type 1 Diabetes: Sociodemographic Factors and Parent-Reported Barriers. Diabetes Technol Ther. 2017 06; 19(6):363-369.
    View in: PubMed
    Score: 0.128
  12. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. Lancet. 2017 01 28; 389(10067):369-380.
    View in: PubMed
    Score: 0.124
  13. Early Detection of Infusion Set Failure During Insulin Pump Therapy in Type 1 Diabetes. J Diabetes Sci Technol. 2016 11; 10(6):1268-1276.
    View in: PubMed
    Score: 0.123
  14. Duration of Infusion Set Survival in Lipohypertrophy Versus Nonlipohypertrophied Tissue in Patients with Type 1 Diabetes. Diabetes Technol Ther. 2016 07; 18(7):429-35.
    View in: PubMed
    Score: 0.119
  15. Overnight glucose control with an automated, unified safety system in children and adolescents with type 1 diabetes at diabetes camp. Diabetes Care. 2014 Aug; 37(8):2310-6.
    View in: PubMed
    Score: 0.104
  16. Two Years with a Tubeless Automated Insulin Delivery System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 Diabetes. Diabetes Technol Ther. 2024 01; 26(1):11-23.
    View in: PubMed
    Score: 0.050
  17. Safety and Glycemic Outcomes With a Tubeless Automated Insulin Delivery System in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Clinical Trial. Diabetes Care. 2022 08 01; 45(8):1907-1910.
    View in: PubMed
    Score: 0.046
  18. Clinical and Demographic Factors Associated With Diabetic Retinopathy Among Young Patients With Diabetes. JAMA Netw Open. 2021 09 01; 4(9):e2126126.
    View in: PubMed
    Score: 0.043
  19. Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes. Diabetes Care. 2021 07; 44(7):1630-1640.
    View in: PubMed
    Score: 0.042
  20. A Real-World Prospective Study of the Safety and Effectiveness of the Loop Open Source Automated Insulin Delivery System. Diabetes Technol Ther. 2021 05; 23(5):367-375.
    View in: PubMed
    Score: 0.042
  21. Characteristics of adult- compared to childhood-onset type 1 diabetes. Diabet Med. 2020 12; 37(12):2109-2115.
    View in: PubMed
    Score: 0.039
  22. Time spent outside of target glucose range for young children with type 1 diabetes: a continuous glucose monitor study. Diabet Med. 2020 08; 37(8):1308-1315.
    View in: PubMed
    Score: 0.039
  23. The Transatlantic HbA1c gap: differences in glycaemic control across the lifespan between people included in the US T1D Exchange Registry and those included in the German/Austrian DPV registry. Diabet Med. 2020 05; 37(5):848-855.
    View in: PubMed
    Score: 0.038
  24. Greater parental comfort with lower glucose targets in young children with Type 1 diabetes using continuous glucose monitoring. Diabet Med. 2019 11; 36(11):1508-1510.
    View in: PubMed
    Score: 0.037
  25. Effect of acetaminophen on CGM glucose in an outpatient setting. Diabetes Care. 2015 Oct; 38(10):e158-9.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.